Home
CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

Today’s Highlights April 21, 2023

Important News from CymaBay Therapeutics
Primary Biliary Cholangitis
Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that results from the ENHANCE phase 3 global study evaluating seladelpar for Primary Biliary Cholangitis (PBC) have been published in Hepatology. The authors . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
April 21, 2023

Other Articles